Do evisceration with primary implant placement in patients with endophthalmitis?
Based on the low overall complication rate in the present study (12%), the ease of evisceration, the convenience of a single procedure, the rapid resolution of infection, and the successful retention of the implant in most of our patients, it is plausible to offer evisceration with primary implant placement to patients with recalcitrant endophthalmitis or panophthalmitis. This would avoid a secondary surgical intervention in most patients, as opposed to delayed secondary implantation, in which case 100% of the patients would require, at least theoretically, another intervention.
In atherosclerosis-prone mice, PAI-1 promotes neointima formation after oxidative vascular injury. The apparent hyperlipidemia-dependent effect of PAI-1 may be mediated by its capacity to inhibit the clearance of platelet-fibrin thrombi that can deliver growth factors to the blood vessel wall or be incorporated into developing vascular lesions. Alternatively, hyperlipidemia may alter the pattern of gene expression in the blood vessel wall to enhance potential effects of PAI-1 on antiproliferative processes, such as transforming growth factor-beta activation and apoptosis.